Business Context and Reporting Period
This Form 6-K filing by Alcon, Inc. (a Swiss corporation and majority-owned subsidiary of Novartis AG) covers the three-month and nine-month periods ended September 30, 2010. The filing includes unaudited condensed consolidated financial statements and management's discussion and analysis. A significant corporate event during this period was the consummation of Novartis's purchase of Nestlé's remaining Alcon shares in August 2010, resulting in a change of majority ownership and triggering specific change-of-control provisions in employee benefit plans and share-based compensation.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2010 | Nine Months Ended Sept 30, 2010 |
|---|---|---|
| Sales (Revenue) | $1,760 million | $5,367 million |
| Gross Profit | $1,338 million (76.0% margin) | $4,127 million (76.9% margin) |
| Operating Income | $495 million | $1,899 million |
| Net Earnings | $446 million | $1,689 million |
| Diluted EPS | $1.47 | $5.56 |
| Operating Cash Flow | N/A | $1,764 million |
| Cash and Cash Equivalents (Sept 30, 2010) | $2,196 million | |
| Total Debt (Short-term + Current Maturities) | $342 million |
Material Changes vs. Prior Period
- Revenue Growth: Global sales increased 9.0% in the third quarter and 12.2% for the nine-month period compared to 2009. Growth was driven by volume increases and price hikes, partially offset by unfavorable foreign exchange rates in the quarter (though favorable for the nine-month period).
- Profitability Decline (Q3): Operating income decreased 14.4% in the third quarter to $495 million, primarily due to $133 million in "Other operating expenses" related to the change of control (Novartis acquisition) and merger proposal evaluation costs. This included $97 million in accelerated pension costs and $8 million in share-based compensation.
- Profitability Increase (9M): Despite the Q3 drag, nine-month operating income increased 10.2% to $1,899 million, driven by sales growth, disciplined cost management, and a $24 million favorable adjustment to royalty estimates.
- Acquisitions: The company acquired LenSx Lasers, Inc. in August 2010 for a total purchase price of $451 million (including contingent payments), adding femtosecond laser technology to its surgical portfolio.
Guidance, Outlook, Risks, and Unusual Items
- Change of Control Costs: The filing details significant one-time costs associated with Novartis acquiring Nestlé's stake. This included a $152 million cash contribution to the Alcon Executive Retirement Plans Grantor Trust and the acceleration of pension and equity compensation expenses.
- Merger Proposal: Novartis proposed a merger of Alcon with and into Novartis. The Alcon Independent Director Committee rejected the proposal in January 2010, citing unacceptable terms. A $50 million Litigation Trust was funded to protect minority shareholder interests regarding this transaction.
- U.S. Healthcare Reform: New legislation enacted in March 2010 increased Medicaid rebates and imposed new fees. Management estimates these provisions decreased sales by $20 million in 2010 and resulted in a $25 million tax charge due to the elimination of a subsidy tax benefit.
- Legal Contingencies: The company faces patent infringement lawsuits from generic drug manufacturers regarding products like Vigamox, Patanol, and Travatan. While management believes it has valid defenses, adverse rulings could significantly impact future sales. Additionally, minority shareholder class action lawsuits regarding the Novartis merger proposal are pending.
- Product Recall: A voluntary Class 1 recall was initiated for the CONSTELLATION vision system; management does not expect a material financial impact.
Investor Verification Checklist
- Change of Control Impact: Verify the full extent of one-time charges related to the Novartis acquisition and whether similar costs will recur in future periods.
- Merger Status: Monitor the status of the rejected Novartis merger proposal and the potential for a revised offer or litigation outcomes involving the Litigation Trust.
- Patent Litigation: Review the status of pending patent challenges for key products (Vigamox, Patanol, Travatan) and the potential timeline for generic entry.
- Healthcare Reform Exposure: Assess the long-term impact of U.S. healthcare reform on rebate levels, the 2.3% medical device excise tax (effective 2013), and the pharmaceutical industry fee.
- LenSx Integration: Evaluate the commercial performance and milestone achievement probability for the newly acquired LenSx Lasers technology.